Conduct by life science companies has long been the subject of intense antitrust scrutiny, with focus in recent years on what some perceive to be high drug prices enabled by anticompetitive acquisitions, sometimes branded as “killer acquisitions,” and conduct that prevents or delays generic entry. With the incoming Biden Administration, signs abound that this scrutiny is very likely to reach new levels in 2021 and beyond.

This webinar will discuss the latest trends relating to antitrust enforcement in life sciences from federal and state enforcers to private plaintiffs and offer guidance for navigating these increasingly hostile waters.

Find out more and register.